Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
- Dowsett, Mitch, Allred, Craig, Bishop, Hugh, Ellis, Ian, Larsimont, Danis, Sasano, Hironobu, Carder, Pauline, Cussac, Antonio L., Knox, Fiona, Speirs, Valerie, Forbes, John, Buzdar, Aman, Knox, Jill, Quinn, Emma, Salter, Janine, Wale, Chris, Cuzick, Jack, Houghton, Joan, Williams, Norman, Mallon, Elizabeth
- Zito, Francesco Alfredo, Verderio, Paolo, Pennelli, Natale, Pezzica, Ezio, Vezzosi, Vania, Ventrella, Vincenzo, Pizzamiglio, Sara, Paradiso, Angelo, Ellis, Ian, Simone, Giovanni, Angione, Vito, Apicella, Paola, Bianchi, Simonetta, Conde, Antonio Felix, Hameed, Omar, Ibarra, Julio, Leong, Antony
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial
- Forbes, John F., Sestak, Ivana, Holcombe, Chris, Coleman, Robert E., Jones, Louise, Ellis, Ian, Cuzick, Jack, Howell, Anthony, Bonanni, Bernardo, Bundred, Nigel, Levy, Christelle, von Minckwitz, Gunter, Eiermann, Wolfgang, Neven, Patrick, Stierer, Michael
Are you sure you would like to clear your session, including search history and login status?